TuHURA Biosciences (NASDAQ:HURA) Shares Down 2.6% – Here’s What Happened

TuHURA Biosciences (NASDAQ:HURA)’s share price dropped 2.6% during mid-day trading on Thursday . The stock traded as low as $4.66 and last traded at $4.92. Approximately 320,091 shares changed hands during trading, an increase of 42% from the average daily volume of 224,917 shares. The stock had previously closed at $5.05.

Wall Street Analysts Forecast Growth

HURA has been the subject of several recent research reports. Rodman & Renshaw initiated coverage on TuHURA Biosciences in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Maxim Group initiated coverage on TuHURA Biosciences in a report on Tuesday, November 5th. They set a “buy” rating and a $15.00 price target for the company. Finally, RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th.

TuHURA Biosciences Price Performance

The stock’s 50 day simple moving average is $4.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TuHURA Biosciences stock. Apollon Wealth Management LLC acquired a new stake in TuHURA Biosciences (NASDAQ:HURA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 61,772 shares of the company’s stock, valued at approximately $253,000. Apollon Wealth Management LLC owned 0.15% of TuHURA Biosciences at the end of the most recent reporting period. 0.62% of the stock is owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.